David M. Jackman

12.5k total citations · 4 hit papers
87 papers, 7.6k citations indexed

About

David M. Jackman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, David M. Jackman has authored 87 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Pulmonary and Respiratory Medicine, 50 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in David M. Jackman's work include Lung Cancer Treatments and Mutations (59 papers), Lung Cancer Research Studies (25 papers) and Lung Cancer Diagnosis and Treatment (23 papers). David M. Jackman is often cited by papers focused on Lung Cancer Treatments and Mutations (59 papers), Lung Cancer Research Studies (25 papers) and Lung Cancer Diagnosis and Treatment (23 papers). David M. Jackman collaborates with scholars based in United States, United Kingdom and Netherlands. David M. Jackman's co-authors include Bruce E. Johnson, Pasi A. Jänne, Geoffrey R. Oxnard, Beow Y. Yeap, Suzanne E. Dahlberg, Lecia V. Sequist, Neal I. Lindeman, Michael S. Rabin, Mohit Butaney and Thomas J. Lynch and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

David M. Jackman

86 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

2009 644 citations David M. Jackman, Pasi A. Jänne et al. Journal of Clinical Oncology profile →
Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

2014 590 citations Geoffrey R. Oxnard, Cloud P. Paweletz et al. Clinical Cancer Research profile →
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

2018 539 citations David M. Jackman, Lecia V. Sequist et al. Journal of Clinical Oncology profile →
MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

2016 493 citations Geoffrey R. Oxnard, David M. Jackman et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David M. Jackman United States	38	5.6k	4.9k	2.0k	1.7k	433	87	7.6k
Rogério Lilenbaum United States	33	5.5k 1.0×	5.6k 1.1×	2.1k 1.1×	1.2k 0.7×	421 1.0×	105	8.4k
M. Pérol France	33	5.4k 1.0×	4.7k 0.9×	1.5k 0.7×	1.3k 0.8×	506 1.2×	292	7.0k
Rafał Dziadziuszko Poland	44	6.3k 1.1×	5.8k 1.2×	2.7k 1.3×	1.8k 1.1×	557 1.3×	290	9.0k
Haiyi Jiang Japan	24	8.2k 1.5×	6.8k 1.4×	2.4k 1.2×	2.1k 1.3×	475 1.1×	53	9.9k
Renato Martins United States	20	4.7k 0.8×	4.6k 0.9×	1.7k 0.8×	916 0.6×	302 0.7×	42	6.7k
Chun‐Ming Tsai Taiwan	31	6.4k 1.1×	5.3k 1.1×	2.0k 1.0×	1.4k 0.9×	394 0.9×	114	7.8k
Rafael Rosell Spain	43	4.8k 0.9×	4.3k 0.9×	3.2k 1.6×	1.7k 1.0×	630 1.5×	144	8.0k
Daniel de Castro Spain	9	4.5k 0.8×	6.0k 1.2×	1.7k 0.8×	1.7k 1.0×	319 0.7×	26	7.8k
Wilfried Eberhardt Germany	39	5.3k 0.9×	4.2k 0.9×	1.7k 0.8×	892 0.5×	369 0.9×	239	7.6k
Mircea Dediu Romania	19	5.1k 0.9×	4.8k 1.0×	1.6k 0.8×	894 0.5×	289 0.7×	55	6.6k

Countries citing papers authored by David M. Jackman

Since Specialization

Citations

This map shows the geographic impact of David M. Jackman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Jackman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Jackman more than expected).

Fields of papers citing papers by David M. Jackman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Jackman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Jackman. The network helps show where David M. Jackman may publish in the future.

Co-authorship network of co-authors of David M. Jackman

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Jackman. A scholar is included among the top collaborators of David M. Jackman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Jackman. David M. Jackman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cotner, Cody E., Angela C. Tramontano, Charlotta Lindvall, et al.. (2024). Using Oncology Treatment Pathway Data to Evaluate Serious Illness Communication, Care Utilization, and End-of-Life Care for Patients With Cancer. JCO Oncology Practice. 21(4). 535–543. 3 indexed citations

Yanagita, Masahiko, Amanda J. Redig, Cloud P. Paweletz, et al.. (2016). A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Clinical Cancer Research. 22(24). 6010–6020. 92 indexed citations

Li, Richard, Gretchen Hermann, Elizabeth H. Baldini, et al.. (2016). Advanced nodal stage predicts venous thromboembolism in patients with locally advanced non-small cell lung cancer. Lung Cancer. 96. 41–47. 16 indexed citations

Calles, Antonio, Lynette M. Sholl, Scott J. Rodig, et al.. (2015). Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS -Mutant Lung Adenocarcinoma. Clinical Cancer Research. 21(12). 2851–2860. 86 indexed citations

Linehan, W. Marston, Stephanie Cardarella, Christine Lydon, et al.. (2015). Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. Journal of Thoracic Oncology. 11(4). 556–565. 252 indexed citations

Oxnard, Geoffrey R., Cloud P. Paweletz, Yanan Kuang, et al.. (2014). Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA. Clinical Cancer Research. 20(6). 1698–1705. 590 indexed citations breakdown →

Oxnard, Geoffrey R., Peter Lo, Mizuki Nishino, et al.. (2013). Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions. Journal of Thoracic Oncology. 8(2). 179–184. 261 indexed citations

Nishino, Mizuki, Suzanne E. Dahlberg, Stephanie Cardarella, et al.. (2013). Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI. Journal of Thoracic Oncology. 8(8). 1059–1068. 44 indexed citations

Cardarella, Stephanie, Taylor M. Ortiz, Victoria A. Joshi, et al.. (2012). The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 7(12). 1767–1774. 77 indexed citations

10.

Gill, Ritu R., Stéphanie Héon, Beow Y. Yeap, et al.. (2012). Genomic profiling of non-small cell lung cancer (NSCLC) for personalized targeted therapy using CT-guided transthoracic needle biopsy (TTNB).. Journal of Clinical Oncology. 30(15_suppl). 10592–10592. 3 indexed citations

11.

Nishino, Mizuki, David M. Jackman, Hiroto Hatabu, et al.. (2011). Imaging of Lung Cancer in the Era of Molecular Medicine. Academic Radiology. 18(4). 424–436. 29 indexed citations

12.

Jackman, David M.. (2009). Current Options for Systemic Therapy in Mesothelioma. Seminars in Thoracic and Cardiovascular Surgery. 21(2). 154–158. 12 indexed citations

13.

Souza, Frederico, et al.. (2009). Recurrent malignant peritoneal mesothelioma: radiological manifestations. Abdominal Imaging. 35(3). 315–321. 10 indexed citations

14.

Yonesaka, Kimio, Kreshnik Zejnullahu, Neal I. Lindeman, et al.. (2008). Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers. Clinical Cancer Research. 14(21). 6963–6973. 96 indexed citations

15.

Cioffredi, Leigh‐Anne, Pasi A. Jänne, & David M. Jackman. (2008). Treatment of peritoneal mesothelioma in pediatric patients. Pediatric Blood & Cancer. 52(1). 127–129. 11 indexed citations

16.

Jackman, David M., Neal I. Lindeman, Joan Lucca, et al.. (2007). P3-096: Phase II study of erlotinib in chemo–naïve women with advanced pulmonary adenocarcinoma.. Journal of Thoracic Oncology. 2(8). S720–S720. 1 indexed citations

17.

Jackman, David M., Beow Y. Yeap, Lecia V. Sequist, et al.. (2006). Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. Clinical Cancer Research. 12(13). 3908–3914. 491 indexed citations

18.

Nakabayashi, Mari, Wanling Xie, Meredith M. Regan, et al.. (2006). Response to low‐dose ketoconazole and subsequent dose escalation to high‐dose ketoconazole in patients with androgen‐independent prostate cancer. Cancer. 107(5). 975–981. 35 indexed citations

19.

Koo, Douglas J., David M. Jackman, Irshad H. Chaudry, & Ping Wang. (2001). Adrenal insufficiency during the late stage of polymicrobial sepsis. Critical Care Medicine. 29(3). 618–622. 51 indexed citations

20.

Koo, Douglas J., Mian Zhou, David M. Jackman, et al.. (1999). Is gut the major source of proinflammatory cytokine release during polymicrobial sepsis?. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1454(3). 289–295. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact